VYEPTI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYEPTI (VYEPTI).
VYEPTI (eptinezumab-jjmr) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated vasodilation and nociceptive signaling implicated in migraine pathogenesis.
| Metabolism | Eptinezumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or CYP450 enzyme involvement. |
| Excretion | Eptinezumab (VYEPTI) is expected to be catabolized into small peptides and amino acids. No renal or biliary excretion of intact drug occurs; elimination is via general protein degradation pathways. |
| Half-life | Terminal elimination half-life is approximately 27 days (range: 23–33 days), supporting quarterly intravenous dosing for migraine prophylaxis. |
| Protein binding | Approximately 97% bound to plasma proteins; specific binding proteins not characterized, but typical for monoclonal antibodies: primarily to immunoglobulins and albumin. |
| Volume of Distribution | Volume of distribution is approximately 3.7 L (0.05 L/kg for a 70 kg adult), indicating limited extravascular distribution, consistent with a monoclonal antibody primarily confined to the vascular and interstitial spaces. |
| Bioavailability | Intravenous administration yields 100% bioavailability. Subcutaneous and intramuscular routes are not approved; no bioavailability data for other routes. |
| Onset of Action | Intravenous infusion: onset of clinical effect (reduction in migraine frequency) observed as early as Day 1 post-infusion, with significant benefit over placebo by Week 1. |
| Duration of Action | Duration of effect persists for approximately 3 months (one dosing interval), with maintained efficacy over repeated quarterly doses. Clinical trials show sustained reduction in migraine days across consecutive 12-week cycles. |
| Molecular Weight | 150000 |
100 mg as an intravenous infusion over 30 seconds every 12 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended in patients with mild to moderate renal impairment (CrCl >=30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment recommended for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not studied in severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No dose adjustment required based on age. Clinical studies included patients aged 65 years and older, but limited data suggest no overall differences in safety or efficacy. |
| 1st trimester | Limited human data; based on mechanism, potential for fetal harm due to inhibition of CGRP, which may be involved in placental development and fetal growth. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Similar concerns as first trimester; avoid use unless clearly needed. |
| 3rd trimester | Potential risk of fetal harm; avoid use during third trimester due to possible effects on uterine blood flow and fetal development. |
Clinical note
Comprehensive clinical and safety monograph for VYEPTI (VYEPTI).
| Placental transfer | High molecular weight (approximately 150 kDa) suggests minimal placental transfer, but IgG antibodies can cross via FcRn receptors. Limited data, but potential for transfer increases with gestational age. |
| Breastfeeding | No data on presence in human milk, effects on infant, or milk production. Given high molecular weight, excretion likely minimal, but caution recommended. Weigh benefits against potential risks. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to eptinezumab or any excipient
| Precautions | Hypersensitivity reactions including angioedema, urticaria, flushing, and rash have been reported; discontinue if severe reaction occurs., Potential for immunogenicity (development of antidrug antibodies) which may affect efficacy or safety. |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | VYEPTI (eptinezumab-jjmr) is a CGRP antagonist monoclonal antibody for migraine prevention. Administer intravenously over 30 minutes. Monitor for hypersensitivity reactions. Not for acute migraine treatment. Renal/hepatic impairment not studied; no dose adjustment in mild-to-moderate renal impairment. Pregnancy: limited data, use if benefit outweighs risk. Contraindicated if history of hypersensitivity to eptinezumab or excipients. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate human data. In animal studies, eptinezumab showed no evidence of fetal harm at doses up to 100 mg/kg IV (13 times the human exposure based on AUC) during organogenesis. Due to IgG structure, minimal transfer in first trimester; active transfer increases in second and third trimesters. Theoretical risk of fetal immune system effects. Risk cannot be excluded. |
| Fetal Monitoring | No specific monitoring required. Standard prenatal care. Monitor for hypersensitivity reactions during infusion. Consider monitoring for infections in neonate if used in late pregnancy due to potential immune effects. |
| Fertility Effects | In animal studies, no adverse effects on male or female fertility at doses up to 100 mg/kg IV. Human data not available. Theoretical risk based on mechanism (CGRP inhibition) but no evidence of fertility impairment. |
| Patient Advice | VYEPTI is given as an IV infusion every 3 months to prevent migraines. · It does not treat a migraine attack that has already started. · Common side effects include nasal congestion, sore throat, and allergic reactions. · Seek immediate medical attention if you experience hives, difficulty breathing, or swelling of face/mouth. · Tell your doctor if you are pregnant, breastfeeding, or have a history of allergic reactions. |